COVID-19 infection in a patientwith Cushing's disease on osilodrostat treatment

被引：1
|
作者：
Boguslawska, Anna [1 ]
Minasyan, Mari [2 ]
Hubalewska-Dydejczyk, Alicja [1 ]
Gilis-Januszewska, Aleksandra [1 ,3 ]
机构：
[1] Jagiellonian Univ, Chair & Dept Endocrinol, Med Coll, Krakow, Poland
[2] Univ Hosp, Endocrinol Oncol Endocrinol & Nucl Med Dept, Krakow, Poland
[3] Ul Jakubowskiego 2, Krakoow, Poland
来源：
ENDOKRYNOLOGIA POLSKA | 2023年 / 74卷 / 03期
关键词：
COVID-19; Cushing's disease; osilodrostat; MANAGEMENT;
D O I：
10.5603/EP.a2023.0041
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：342 / 343
页数：2
相关论文
共 50 条
  • [1] Osilodrostat for the treatment of Cushing's disease
    Rasool, Syeda
    Skinner, Brian W.
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (09) : 1099 - 1106
  • [2] Osilodrostat (Isturisa) for Cushing's Disease
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2021, 63 (1617): : 21 - 23
  • [3] Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence
    Chabre, Olivier
    Muller, Marie
    Cristante, Justine
    Cracowski, Jean-Luc
    Gay, Emmanuel
    LANCET DIABETES & ENDOCRINOLOGY, 2022, 10 (06): : 384 - 385
  • [4] Osilodrostat: 11β-hydroxylase inhibitor for treatment of Cushing's disease
    Paton, D. M.
    DRUGS OF TODAY, 2020, 56 (10) : 643 - 654
  • [5] A case of severe Covid-19 infection as the first manifestation of Cushing's disease
    Lopes, Maria Leonor Guia
    Cidade, Jose Pedro
    Antunes, Carolina
    Limbert, Clotilde
    Duarte, Joao Sequeira
    ENDOCRINOLOGY DIABETES AND METABOLISM CASE REPORTS, 2024, 2024 (04):
  • [6] Randomized Trial of Osilodrostat for the Treatment of Cushing Disease
    Gadelha, Monica
    Bex, Marie
    Feelders, Richard A.
    Heaney, Anthony P.
    Auchus, Richard J.
    Gilis-Januszewska, Aleksandra
    Witek, Przemyslaw
    Belaya, Zhanna
    Yu, Yerong
    Liao, Zhihong
    Ku, Chih Hao Chen
    Carvalho, Davide
    Roughton, Michael
    Wojna, Judi
    Pedroncelli, Alberto M.
    Snyder, Peter J.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (07): : E2882 - E2895
  • [7] Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence Reply
    Fleseriu, Maria
    Castinetti, Frederic
    Gadelha, Monica
    Giustina, Andrea
    Lacroix, Andre
    Melmed, Shlomo
    Newell-Price, John
    Pivonello, Rosario
    Reincke, Martin
    Biller, Beverly M. K.
    LANCET DIABETES & ENDOCRINOLOGY, 2022, 10 (06): : 385 - 387
  • [8] Cushing's syndrome and COVID-19
    Attia, Amina
    Bertherat, Jerome
    PITUITARY, 2024, : 945 - 954
  • [9] Osilodrostat oral tablets for adults with Cushing's disease
    Martino, Marianna
    Aboud, Nairus
    Lucchetti, Beatrice
    Salvio, Gianmaria
    Arnaldi, Giorgio
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2022, 17 (02) : 99 - 109
  • [10] COVID-19 infection in Crohn's disease under treatment with adalimumab
    Tursi, Antonio
    Angarano, Gioacchino
    Monno, Laura
    Saracino, Annalisa
    Signorile, Fabio
    Ricciardi, Aurelia
    Papa, Alfredo
    GUT, 2020, 69 (07) : 1364 - +
12345